Cargando…
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Ruxolitinib cream 1.5% (OPZELURA™) is a topical formulation of ruxolitinib, a potent, selective inhibitor of Janus kinase (JAK)1 and JAK2. The targeting of these kinases is associated with therapeutic benefits in patients with atopic dermatitis (AD). In two identically designed, multinational, phase...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036407/ https://www.ncbi.nlm.nih.gov/pubmed/36538235 http://dx.doi.org/10.1007/s40257-022-00748-2 |